Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 21:38:147-154.
doi: 10.1016/j.ctro.2022.11.010. eCollection 2023 Jan.

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

David J Thomson  1 , Clare Cruickshank  2 , Helen Baines  3 , Russell Banner  4 , Matthew Beasley  5 , Guy Betts  6 , Helen Bulbeck  7 , Frances Charlwood  1 , Judith Christian  8 , Matthew Clarke  1 , Olly Donnelly  9 , Bernadette Foran  10 , Callum Gillies  11 , Clare Griffin  2 , Jarrod J Homer  6 , Johannes A Langendijk  12 , Lip Wai Lee  1 , James Lester  10 , Matthew Lowe  1 , Andrew McPartlin  13 , Elizabeth Miles  14 , Christopher Nutting  2   15 , Nachi Palaniappan  16 , Robin Prestwich  17 , James M Price  1   18 , Clare Roberts  1 , Justin Roe  15   19 , Ramkumar Shanmugasundaram  20 , Rita Simões  14 , Anna Thompson  11 , Catharine West  18 , Lorna Wilson  1 , Jane Wolstenholme  21 , Emma Hall  2
Affiliations

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

David J Thomson et al. Clin Transl Radiat Oncol. .

Abstract

•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Trial schema.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R., Laversanne M., Soerjomataram I., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S90-S96. - PMC - PubMed
    1. Nutting C.M., Morden J.P., Harrington K.J., Urbano T.G., Bhide S.A. at al Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 Feb;12(2):127–136. - PMC - PubMed
    1. Price J., Hall E., West C., Thomson D. TORPEdO - A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer. Clin Oncol (R Coll Radiol) 2020 Feb;32(2):84–88. - PubMed
    1. National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group. Proton Beam Therapy – the Challenges of Delivering High-quality Evidence of Clinical Benefit. Clin Oncol (R Coll Radiol). 2018 May;30(5):280-284. - PubMed

LinkOut - more resources